Press release from Companies
Published: 2025-11-14 13:07:00
SensoDetect AB (publ) today announced the successful completion of its presentation at the Redeye Theme: Medtech & Diagnostics event on 12 November 2025. CEO PA Hedin and Dr. Mohamed Hussein Atwa, Head of Clinical Research, presented the company’s technological evolution, commercial strategy, and transition toward large-scale, population-level neuro-auditory screening.
The session consisted of a 12-minute presentation followed by an 8-minute investor Q&A, with strong engagement from both institutional and private investors. The full presentation is available on Redeye’s platform:
• Traditional ADHD and autism assessments remain slow, subjective, and highly resource dependent.
• Global demand is rising, with increasing rates of late diagnoses.
• SensoDetect addresses this through fast, objective, scalable screening.
SensoDetect demonstrated its BERA-based screening workflow:
• 5–15 min auditory test (patented 13-click protocol).
• <10 second statistical and AI-driven analysis.
• Clear Low / Moderate / High risk output.
Based on over 30 years of psychoacoustic and neuroscience research at Lund University.
• ADHD & Autism markets exceed USD 500B globally.
• Business model: device sales + device placement + per-screening revenue + advanced statistical and AI/cloud services.
• Recurring revenues grow as screening volumes scale.
• Statistical and in-line machine learning models improve AI performance strengthens with every new screening – a self-reinforcing competitive moat.
SensoDetect is transitioning from a niche diagnostic tool to a population-scale screening platform.
Primary environments targeted:
• Private and semi-private schools.
• Large corporations (e.g. personnel with stressful and critical functions)
• Sensodetect owned ADHD clinical support centers for screening
• Early childhood and neonatal screening programs
1. ADHD Clinical Support Centers – high-volume, mixed-diagnostic hubs (also for large corporations).
2. School-Based Screening – partnerships with private school networks and government authorities.
3. Autism & Neonatal Screening – early identification through integration with newborn screening.
• Measures neural timing and brainstem connectivity
• Can detect deviations months or years before behavioral symptoms
• Independent of culture, language, or observer bias
Through Beijing Mind Exploration Medical Technology Co., Ltd., SensoDetect advances:
• Large-scale pilots in Beijing & Guangdong
• Education bureau MOUs
• Local cloud/edge processing for data residency
• NMPA-aligned regulatory roadmap
• Alignment with Vision 2030
• School mass-screening suitability
• Partnerships with major healthcare groups and opening of clinical support centers for screening
• 2024 National School Health Screening Guideline includes mental-health screening pathways
• Full coverage 6 years–Grade 12
• Fast approvals and standardized clinical workflows (DHA/MoHAP)
• Ideal for SensoDetect’s fast and objective test
• Accuracy approaching ~90%
• Multi-condition screening expansion
• Launch of the Neuro Status Index (NSI)
• Integration into neonatal programs
• Scaling international device placement and per-screening revenues
PA Hedin, CEO
"Every parent deserves clarity, not years of uncertainty. When a child struggles, the whole family feels it — and far too many are left waiting for answers that come too late. With SensoDetect, we want to change that. By listening directly to the brain, we can provide fast, objective insights that help children earlier and support parents sooner. Our mission is simple: no family should ever feel lost in the system again. SensoDetect is now well on the way in building the global standard neuro-developmental screening for everyone’s benefit."
Dr. Mohamed Hussein Atwa
"With SensoDetect, we move from subjective observation to measurable brain data, redefining mental-health screening for schools, clinics, and communities worldwide."
For more information or partnership inquiries, please contact:
PA Hedin, CEO Sensodetect AB
+46 (0)46 15 79 04
pa.hedin@sensodetect.com
SensoDetect AB is a MedTech AI company listed on the Spotlight Stock Market, focused on establishing the global standard for objective neuro-auditory brain screening. The company’s technology is based on more than 30 years of research in clinical psychoacoustics and neuroscience from Lund University and is protected by a strong international patent portfolio.
SensoDetect’s core platform uses brainstem auditory response patterns to objectively measure neural function in minutes. The method supports large-scale screening and clinical decision-making in conditions such as ADHD, autism spectrum disorder and other neurodevelopmental and psychiatric conditions—providing measurable signals where traditional diagnostic tools rely heavily on subjective assessment.
In recent years, the company has advanced from research to commercial deployment through strategic partnerships and clinical programs in Europe, the Middle East, and China. The latest generation of the system, including BERA 4.2 and integrated AI analysis, enables faster testing, greater scalability, and the ability to support national-level screening initiatives in healthcare, schools, and preventive medicine.
SensoDetect’s mission is to increase diagnostic accuracy, reduce waiting times, and support healthcare systems in managing the rapidly growing global need for mental and neurodevelopmental health evaluation. The company aims to make objective brain screening accessible at scale—improving outcomes for patients, families, and society.
More info at https://www.sensodetect.com/
